DWA
GMAB icon

Dorsey Wright & Associates’s Genmab GMAB Stock Holding History

Dorsey Wright & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,388
Closed -$1.73M – 152
2026
Q1 		$1.73M Buy
64,388
+19,551
+44% +$586K 0.21% 95
2025
Q4 		$1.38M Buy
+44,837
New +$1.4M 0.3% 92
2023
Q1 		– Sell
-87,451
Closed -$3.71M – 324
2022
Q4 		$3.71M Buy
+87,451
New +$3.6M 1.08% 21
2022
Q1 		– Sell
-106,239
Closed -$4.2M – 305
2021
Q4 		$4.2M Sell
106,239
-4,471
-4% -$186K 0.87% 48
2021
Q3 		$4.84M Buy
+110,710
New +$4.97M 1.06% 32
2021
Q1 		– Sell
-84,674
Closed -$3.44M – 308
2020
Q4 		$3.44M Sell
84,674
-1,828
-2% -$68.3K 0.51% 61
2020
Q3 		$3.17M Buy
86,502
+1,167
+1% +$42.2K 0.57% 53
2020
Q2 		$2.85M Buy
+85,335
New +$2.33M 0.58% 51

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dorsey Wright & Associates's GMAB Position: Q2 2026 in Review

Dorsey Wright & Associates sold out of Genmab (GMAB) in Q2 2026, closing a stake of 64,388 shares — an estimated $1.73M sold.

Dorsey Wright & Associates first reported a position in GMAB in Q2 2020 and held it in 8 quarters. The position peaked at $4.84M in Q3 2021. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Dorsey Wright & Associates reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Dorsey Wright & Associates sold 64,388 Genmab shares in Q2 2026, an estimated $1.73M.
  • Dorsey Wright & Associates first reported a position in Genmab in Q2 2020 and held it in 8 quarters.
  • Dorsey Wright & Associates's Genmab position peaked at $4.84M in Q3 2021.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.